In the past week, ALVR stock has gone down by -1.30%, with a monthly gain of 2.93% and a quarterly plunge of -3.23%. The volatility ratio for the week is 6.43%, and the volatility levels for the last 30 days are 5.29% for AlloVir Inc The simple moving average for the past 20 days is -1.92% for ALVR’s stock, with a 4.37% simple moving average for the past 200 days.
Is It Worth Investing in AlloVir Inc (NASDAQ: ALVR) Right Now?
ALVR has 36-month beta value of 0.78. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 2 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALVR is 58.13M, and currently, short sellers hold a 9.47% ratio of that float. The average trading volume of ALVR on October 16, 2024 was 166.56K shares.
ALVR) stock’s latest price update
AlloVir Inc (NASDAQ: ALVR) has experienced a decline in its stock price by -8.41 compared to its previous closing price of 0.85. However, the company has seen a fall of -1.30% in its stock price over the last five trading days. globenewswire.com reported 2024-09-16 that NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of AlloVir, Inc. (NASDAQ: ALVR) breached their fiduciary duties to shareholders.
Analysts’ Opinion of ALVR
Many brokerage firms have already submitted their reports for ALVR stocks, with BofA Securities repeating the rating for ALVR by listing it as a “Underperform.” The predicted price for ALVR in the upcoming period, according to BofA Securities is $1 based on the research report published on December 26, 2023 of the previous year 2023.
ALVR Trading at 1.51% from the 50-Day Moving Average
After a stumble in the market that brought ALVR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.52% of loss for the given period.
Volatility was left at 5.29%, however, over the last 30 days, the volatility rate increased by 6.43%, as shares surge +4.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.02% upper at present.
During the last 5 trading sessions, ALVR fell by -1.30%, which changed the moving average for the period of 200-days by +15.04% in comparison to the 20-day moving average, which settled at $0.7976. In addition, AlloVir Inc saw 15.08% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALVR starting from Sinha Vikas, who sale 940 shares at the price of $0.81 back on Oct 03 ’24. After this action, Sinha Vikas now owns 1,152,644 shares of AlloVir Inc, valued at $766 using the latest closing price.
Miller Edward, the General Counsel of AlloVir Inc, sale 377 shares at $0.81 during a trade that took place back on Oct 03 ’24, which means that Miller Edward is holding 215,604 shares at $307 based on the most recent closing price.
Stock Fundamentals for ALVR
Current profitability levels for the company are sitting at:
- -14.43 for the present operating margin
- 0.55 for the gross margin
The net margin for AlloVir Inc stands at -16.75. The total capital return value is set at -0.94. Equity return is now at value -80.33, with -67.85 for asset returns.
Based on AlloVir Inc (ALVR), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -13.43. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -59.03.
Currently, EBITDA for the company is -180.93 million with net debt to EBITDA at 0.79. When we switch over and look at the enterprise to sales, we see a ratio of -0.65. The receivables turnover for the company is 87.29for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 55.08.
Conclusion
To put it simply, AlloVir Inc (ALVR) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
